Novel investigational agents for the treatment of scleroderma

Expert Opinion on Investigational Drugs

Volumn 23, Issue 2, 2014, Pages 183-198

  McMahan, Zsuzsanna Hortobagyi ^a   Wigley, Fredrick M ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Drugs; Immunomodulatory; Novel therapies; Scleroderma; Systemic sclerosis; Treatment

Indexed keywords

ABATACEPT; ANGIOTENSIN 2 RECEPTOR; BELIMUMAB; BETA CATENIN; BLEOMYCIN; BORTEZOMIB; CONNECTIVE TISSUE GROWTH FACTOR; DERMATOLOGICAL AGENT; IMMUNOGLOBULIN; IMMUNOMODULATING AGENT; INTERLEUKIN 13 ANTIBODY; INTERLEUKIN 4; JANUS KINASE 2 INHIBITOR; LYSOPHOSPHATIDIC ACID; OSTEOPONTIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIRFENIDONE; PLACEBO; PROTEIN TYROSINE KINASE INHIBITOR; RAPAMYCIN; RHO KINASE INHIBITOR; RITUXIMAB; SONIC HEDGEHOG PROTEIN; THALIDOMIDE DERIVATIVE; THROMBIN; TOCILIZUMAB; TRANSFORMING GROWTH FACTOR BETA; UNINDEXED DRUG;

AUTOIMMUNITY; EXPERIMENTAL FIBROSIS; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; IN VITRO STUDY; NONHUMAN; REVIEW; SCLERODERMA; SKIN DISEASE; SKIN FIBROSIS; SUMOYLATION; THERAPY; VASCULAR DISEASE; VISUAL ANALOG SCALE;

ANIMALS; CARDIOVASCULAR AGENTS; CYTOKINES; DRUGS, INVESTIGATIONAL; HUMANS; IMMUNOLOGIC FACTORS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; SCLERODERMA, SYSTEMIC;

EID: 84892403410     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2014.848852     Document Type: Review

References (120)

1. Milano A, Pendergrass SA, Sargent JL, et al. Molecular subsets in the gene expression signatures of scleroderma skin. PLoS One 2008;3:e2696
2. Whitfield ML, Finlay DR, Murray JI, et al. Systemic and cell type-specific gene expression patterns in scleroderma skin. Proc Natl Acad Sci USA 2003; 100:12319-24 (Pubitemid 37271558)
3. Bhattacharyya S, Wei J, Varga J. Understanding fibrosis in systemic sclerosis: shifting paradigms, emerging opportunities. Nat Rev Rheumatol 2011;8:42-54
4. Blobe GC, Schiemann WP, Lodish HF. Role of transforming growth factor beta in human disease. N Engl J Med 2000; 342:1350-8 (Pubitemid 30408720)
5. Abraham DJ, Krieg T, Distler J, et al. Overview of pathogenesis of systemic sclerosis. Rheumatology (Oxford) 2009; 48(Suppl 3):iii3-7
6. Prescott RJ, Freemont AJ, Jones CJ, et al. Sequential dermal microvascular and perivascular changes in the development of scleroderma. J Pathol 1992;166:255-63
7. Trotta F, Biagini G, Cenacchi G, et al. Microvascular changes in progressive systemic sclerosis: immunohistochemical and ultrastructural study. Clin Exp Rheumatol 1984;2:209-15 (Pubitemid 14016362)
8. Pattanaik D, Brown M, Postlethwaite AE. Vascular involvement in systemic sclerosis (scleroderma). J Inflamm Res 2011;4:105-25
9. Rabquer BJ, Koch AE. Angiogenesis and vasculopathy in systemic sclerosis: evolving concepts. Curr Rheumatol Rep 2012;14:56-63
10. Fleming JN, Schwartz SM. The pathology of scleroderma vascular disease. Rheum Dis Clin North Am 2008; 34:41-55; vi (Pubitemid 351337630)
11. Shah AA, Wigley FM. My approach to the treatment of scleroderma. Mayo Clin Proc 2013;88:377-93
12. Baleva M, Nikolov K. The role of intravenous immunoglobulin preparations in the treatment of systemic sclerosis. Int J Rheumatol 2011; 2011:829751
13. Yamamoto T, Takagawa S, Katayama I, et al. Anti-sclerotic effect of transforming growth factor-beta antibody in a mouse model of bleomycin-induced scleroderma. Clin Immunol 1999; 92:6-13 (Pubitemid 29315981)
14. Blank M, Levy Y, Amital H, et al. The role of intravenous immunoglobulin therapy in mediating skin fibrosis in tight skin mice. Arthritis Rheum 2002; 46:1689-90 (Pubitemid 34620218)
15. Levy Y, Amital H, Langevitz P, et al. Intravenous immunoglobulin modulates cutaneous involvement and reduces skin fibrosis in systemic sclerosis: an openlabel study. Arthritis Rheum 2004; 50:1005-7 (Pubitemid 38326203)
16. Nacci F, Righi A, Conforti ML, et al. Intravenous immunoglobulins improve the function and ameliorate joint involvement in systemic sclerosis: a pilot study. Ann Rheum Dis 2007;66:977-9 (Pubitemid 46999806)
17. Amital H, Rewald E, Levy Y, et al. Fibrosis regression induced by intravenous gammaglobulin treatment. Ann Rheum Dis 2003;62:175-7 (Pubitemid 36135396)
18. Bodemer C, Teillac D, Le Bourgeois M, et al. Efficacy of intravenous immunoglobulins in sclerodermatomyositis. Br J Dermatol 1990;123:545-6
19. IVIG treatment in systemic sclerosis. [Internet]. Washington, D.C.: National Institutes of Health. 2013. Available from: http://www.clinicaltrials. gov/ct2/show/NCT01785056term=NCT017850 56&rank=1 [Updated 2 May 2013; Cited 28 January 2013]
20. Gu YS, Kong J, Cheema GS, et al. The immunobiology of systemic sclerosis. Semin Arthritis Rheum 2008;38:132-60
21. Famularo G, Giacomelli R, Alesse E, et al. Polyclonal B lymphocyte activation in progressive systemic sclerosis. J Clin Lab Immunol 1989;29:59-63 (Pubitemid 20186228)
22. Bosello S, De Luca G, Tolusso B, et al. B cells in systemic sclerosis: a possible target for therapy. Autoimmun Rev 2011;10:624-30
23. Sato S, Fujimoto M, Hasegawa M, et al. Altered blood B lymphocyte homeostasis in systemic sclerosis: expanded naive B cells and diminished but activated memory B cells. Arthritis Rheum 2004; 50:1918-27 (Pubitemid 38725103)
24. Daoussis D, Liossis SN, Yiannopoulos G, et al. B-cell depletion therapy in systemic sclerosis: experimental rationale and update on clinical evidence. Int J Rheumatol 2011;2011:214013
25. Daoussis D, Liossis SN, Tsamandas AC, et al. Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study. Rheumatology (Oxford) 2010;49:271-80
26. Daoussis D, Liossis SN, Tsamandas AC, et al. Effect of long-term treatment with rituximab on pulmonary function and skin fibrosis in patients with diffuse systemic sclerosis. Clin Exp Rheumatol 2012;30:S17-22
27. Keir GJ, Maher TM, Hansell DM, et al. Severe interstitial lung disease in connective tissue disease: rituximab as rescue therapy. Eur Respir J 2012; 40:641-8
28. Haroon M, McLaughlin P, Henry M, et al. Cyclophosphamide-refractory scleroderma-associated interstitial lung disease: remarkable clinical and radiological response to a single course of rituximab combined with high-dose corticosteroids. Ther Adv Respir Dis 2011;5:299-304
29. Rituximab in systemic sclerosis. [Internet]. Washington, D.C.: National Institutes of Health. 2013. Available from: http://www.clinicaltrials.gov/ct2/ show/NCT01748084term=NCT01748084&rank=1 [Updated 1 August2013; Cited 10 December 2012]
30. Belimumab for the treatment of diffuse cutaneous systemic sclerosis. [Internet]. Washington, D.C.: National Institutes of Health. 2013. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01670565term= NCT01670565&rank=1 [Updated 13 May 2013; Cited 15 August2012]
31. Takeuchi F, Kawasugi K, Nabeta H, et al. Association of CTLA-4 with systemic sclerosis in japanese patients. Clin Exp Rheumatol 2002;20:823-8 (Pubitemid 35446973)
32. Elhai M, Meunier M, Matucci-Cerinic M, et al. Outcomes of patients with systemic sclerosis-associated polyarthritis and myopathy treated with tocilizumab or abatacept: a EUSTAR observational study. Ann Rheum Dis 2013;72:1217-20
33. A study to evaluate the safety and efficacy of abatacept in patients with diffuse systemic sclerosis (scleroderma). [Internet]. Washington, D.C.: National Institutes of Health. 2011. Available from: http://www.clinicaltrials. gov/ct2/show/NCT00442611term=NCT00442611&rank=1 [Updated 20 July 2011; Cited 1 March 2007]
34. Imatinib in systemic sclerosis. [Internet]. Washington, D.C.: National Institutes of Health. 2012. Available from: http://www.clinicaltrials.gov/ct2/ show/NCT00506831term=NCT00506831&rank=1 [Updated 10 July 2012; Cited 24 July 2007]
35. Beyer C, Distler JH, Distler O. Are tyrosine kinase inhibitors promising for the treatment of systemic sclerosis and other fibrotic diseases Swiss Med Wkly 2010;140:w13050
36. Pope J, McBain D, Petrlich L, et al. Imatinib in active diffuse cutaneous systemic sclerosis: results of a six-month, randomized, double-blind, placebo-controlled, proof-of-concept pilot study at a single center. Arthritis Rheum 2011;63:3547-51
37. Mutlu GM, Budinger GR, Wu M, et al. Proteasomal inhibition after injury prevents fibrosis by modulating TGFbeta( 1) signalling. Thorax 2012;67:139-46
38. Fineschi S, Reith W, Guerne PA, et al. Proteasome blockade exerts an antifibrotic activity by coordinately down-regulating type I collagen and tissue inhibitor of metalloproteinase-1 and up-regulating metalloproteinase-1 production in human dermal fibroblasts. FASEB J 2006;20:562-4 (Pubitemid 46671250)
39. Fineschi S, Bongiovanni M, Donati Y, et al. In vivo investigations on anti-fibrotic potential of proteasome inhibition in lung and skin fibrosis. Am J Respir Cell Mol Biol 2008;39:458-65
40. Koca SS, Ozgen M, Dagli F, et al. Proteasome inhibition prevents development of experimental dermal fibrosis. Inflammation 2012;35:810-7
41. Habashi JP, Doyle JJ, Holm TM, et al. Angiotensin II type 2 receptor signaling attenuates aortic aneurysm in mice through ERK antagonism. Science 2011;332:361-5
42. Brooke BS, Habashi JP, Judge DP, et al. Angiotensin II blockade and aortic-root dilation in marfan's syndrome. N Engl J Med 2008;358:2787-95 (Pubitemid 351930853)
43. Study of the efficacy of losartan on aortic dilatation in patients with marfan syndrome (MARFANSARTAN). [Internet]. Washington, D.C.: National Institutes of Health. 2013. Available from: http://www. clinicaltrials.gov/ct2/ show/NCT00763893term=NCT00763893&rank=1 [Updated 4 March 2013; Cited 30 September 2008]
44. Sule SD, Wigley FM. Treatment of scleroderma: an update. Expert Opin Investig Drugs 2003;12:471-82 (Pubitemid 36336416)
45. Doyle JJ, Gerber EE, Dietz HC. Matrix-dependent perturbation of TGFbeta signaling and disease. FEBS Lett 2012;586:2003-15
46. Shi-wen X, Thompson K, Khan K, et al. Focal adhesion kinase and reactive oxygen species contribute to the persistent fibrotic phenotype of lesional scleroderma fibroblasts. Rheumatology (Oxford) 2012;51:2146-54
47. Honda N, Jinnin M, Kira-Etoh T, et al. miR-150 down-regulation contributes to the constitutive type I collagen overexpression in scleroderma dermal fibroblasts via the induction of integrin beta3. Am J Pathol 2013;182:206-16
48. Horan GS, Wood S, Ona V, et al. Partial inhibition of integrin alpha(v) beta6 prevents pulmonary fibrosis without exacerbating inflammation. Am J Respir Crit Care Med 2008;177:56-65
49. Luzina IG, Todd NW, Nacu N, et al. Regulation of pulmonary inflammation and fibrosis through expression of integrins alphaVbeta3 and alphaVbeta5 on pulmonary T lymphocytes. Arthritis Rheum 2009;60:1530-9
50. Asano Y, Ihn H, Yamane K, et al. Increased expression of integrin alphavbeta5 induces the myofibroblastic differentiation of dermal fibroblasts. Am J Pathol 2006;168:499-510 (Pubitemid 43271148)
51. Asano Y, Ihn H, Jinnin M, et al. Involvement of alphavbeta5 integrin in the establishment of autocrine TGF-beta signaling in dermal fibroblasts derived from localized scleroderma. J Invest Dermatol 2006;126:1761-9 (Pubitemid 44086510)
52. Liu S, Kapoor M, Denton CP, et al. Loss of beta1 integrin in mouse fibroblasts results in resistance to skin scleroderma in a mouse model. Arthritis Rheum 2009;60:2817-21
53. Asano Y, Ihn H, Yamane K, et al. Involvement of alphavbeta5 integrin-mediated activation of latent transforming growth factor beta1 in autocrine transforming growth factor beta signaling in systemic sclerosis fibroblasts. Arthritis Rheum 2005;52:2897-905 (Pubitemid 41369121)
54. Iannone F, Matucci-Cerinic M, Falappone PC, et al. Distinct expression of adhesion molecules on skin fibroblasts from patients with diffuse and limited systemic sclerosis. A pilot study. J Rheumatol 2005;32:1893-8 (Pubitemid 41429018)
55. Loeys BL, Gerber EE, Riegert-Johnson D, et al. Mutations in fibrillin-1 cause congenital scleroderma: stiff skin syndrome. Sci Transl Med 2010;2:23ra20
56. Wei J, Ghosh AK, Sargent JL, et al. PPARgamma downregulation by TGFss in fibroblast and impaired expression and function in systemic sclerosis: a novel mechanism for progressive fibrogenesis. PLoS One 2010;5:e13778
57. Wei J, Bhattacharyya S, Varga J. Peroxisome proliferator-activated receptor gamma: innate protection from excessive fibrogenesis and potential therapeutic target in systemic sclerosis. Curr Opin Rheumatol 2010;22:671-6
58. Ghosh AK, Bhattacharyya S, Lakos G, et al. Disruption of transforming growth factor beta signaling and profibrotic responses in normal skin fibroblasts by peroxisome proliferator-activated receptor gamma. Arthritis Rheum 2004; 50:1305-18 (Pubitemid 38480842)
59. Kulkarni AA, Thatcher TH, Olsen KC, et al. PPAR-gamma ligands repress TGFbeta-induced myofibroblast differentiation by targeting the PI3K/Akt pathway: implications for therapy of fibrosis. PLoS One 2011;6:e15909
60. Kapoor M, McCann M, Liu S, et al. Loss of peroxisome proliferator- activated receptor gamma in mouse fibroblasts results in increased susceptibility to bleomycin-induced skin fibrosis. Arthritis Rheum 2009;60:2822-9
61. Lakota K, Wei J, Carns M, et al. Levels of adiponectin, a marker for PPAR-gamma activity, correlate with skin fibrosis in systemic sclerosis: potential utility as biomarker Arthritis Res Ther 2012;14:R102
62. Wei J, Zhu H, Komura K, et al. A synthetic PPAR-gamma agonist triterpenoid ameliorates experimental fibrosis: PPAR-gamma-independent suppression of fibrotic responses. Ann Rheum Dis 2013; Epub ahead of print
63. Hasegawa M, Sato S, Fujimoto M, et al. Serum levels of interleukin 6 (IL-6), oncostatin M, soluble IL-6 receptor, and soluble gp130 in patients with systemic sclerosis. J Rheumatol 1998; 25:308-13 (Pubitemid 28088260)
64. Muangchan C, Pope JE. Interleukin 6 in systemic sclerosis and potential implications for targeted therapy. J Rheumatol 2012;39:1120-4
65. Shima Y, Kuwahara Y, Murota H, et al. The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab. Rheumatology (Oxford) 2010;49:2408-12
66. A study of RoActemra/Actemra (tocilizumab) versus placebo in patients with systemic sclerosis. [Internet]. Washington, D.C.: National Institutes of Health. 2013. Available from: http://www. clinicaltrials.gov/ct2/show/NCT 01532869term=NCT01532869&rank=1 [Updated 19 August 2013; Cited 10 February 2012]
67. Shi-Wen X, Leask A, Abraham D. Regulation and function of connective tissue growth factor/CCN2 in tissue repair, scarring and fibrosis. Cytokine Growth Factor Rev 2008;19:133-44 (Pubitemid 351382279)
68. Wang Q, Usinger W, Nichols B, et al. Cooperative interaction of CTGF and TGF-beta in animal models of fibrotic disease. Fibrogenesis Tissue Repair 2011; 4:4, 1536-4-4
69. Fan WH, Pech M, Karnovsky MJ. Connective tissue growth factor (CTGF) stimulates vascular smooth muscle cell growth and migration in vitro. Eur J Cell Biol 2000;79:915-23 (Pubitemid 32000725)
70. Ikawa Y, Ng PS, Endo K, et al. Neutralizing monoclonal antibody to human connective tissue growth factor ameliorates transforming growth factor-beta-induced mouse fibrosis. J Cell Physiol 2008;216:680-7
71. Ponticos M, Holmes AM, Shi-wen X, et al. Pivotal role of connective tissue growth factor in lung fibrosis: MAPK-dependent transcriptional activation of type I collagen. Arthritis Rheum 2009;60:2142-55
72. Fuschiotti P, Larregina AT, Ho J, et al. Interleukin-13-producing CD8+ T cells mediate dermal fibrosis in patients with systemic sclerosis. Arthritis Rheum 2013;65:236-46
73. Ishikura K, Yamada N, Ito M, et al. Beneficial acute effects of rho-kinase inhibitor in patients with pulmonary arterial hypertension. Circ J 2006; 70:174-8 (Pubitemid 43170128)
74. Takagi T, Okamoto Y, Tomita S, et al. Intraradial administration of fasudil inhibits augmented rho kinase activity to effectively dilate the spastic radial artery during coronary artery bypass grafting surgery. J Thorac Cardiovasc Surg 2011;142:e59-65
75. Fava A, Wung PK, Wigley FM, et al. Efficacy of rho kinase inhibitor fasudil in secondary raynaud's phenomenon. Arthritis Care Res (Hoboken) 2012; 64:925-9
76. A rho-kinase inhibitor (fasudil) in the treatment of raynaud's phenomenon. [Internet]. Washington, D.C.: National Institutes of Health. 2012. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00498615term= NCT00498615&rank=1 [Updated 29 March 2012; Cited 6 July 2007]
77. LeBlanc R, Hideshima T, Catley LP, et al. Immunomodulatory drug costimulates T cells via the B7-CD28 pathway. Blood 2004; 103:1787-90 (Pubitemid 38268973)
78. Hayashi T, Hideshima T, Akiyama M, et al. Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application. Br J Haematol 2005;128:192-203
79. Saini N, Mahindra A. Novel immunomodulatory compounds in multiple myeloma. Expert Opin Investig Drugs 2013;22:207-15
80. Streetly MJ, Gyertson K, Daniel Y, et al. Alternate day pomalidomide retains anti-myeloma effect with reduced adverse events and evidence of in vivo immunomodulation. Br J Haematol 2008;141:41-51 (Pubitemid 351350609)
81. Schey SA, Fields P, Bartlett JB, et al. Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma. J Clin Oncol 2004;22:3269-76 (Pubitemid 41103682)
82. Weingartner S, Zerr P, Tomcik M, et al. Pomalidomide is effective for prevention and treatment of experimental skin fibrosis. Ann Rheum Dis 2012; 71:1895-9
83. Study of pomalidomide (CC-4047) to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics and effectiveness for subjects with systemic sclerosis with int5erstitial lung disease. [Internet]. Washington, D.C.: National Institutes of Health. 2013. Available from: http://www.clinicaltrials. gov/ct2/show/NCT01559129 term=NCT01559129&rank=1 [Updated 6 April 2013; Cited 19 March 2012]
84. Manno R, Boin F. Immunotherapy of systemic sclerosis. Immunotherapy 2010;2:863-78
85. Yoshizaki A, Yanaba K, Yoshizaki A, et al. Treatment with rapamycin prevents fibrosis in tight-skin and bleomycininduced mouse models of systemic sclerosis. Arthritis Rheum 2010; 62:2476-87
86. Su TI, Khanna D, Furst DE, et al. Rapamycin versus methotrexate in early diffuse systemic sclerosis: results from a randomized, single-blind pilot study. Arthritis Rheum 2009;60:3821-30
87. Rapamycin vs methotrexate in diffuse SSc. [Internet]. Washington, D.C.: National Institutes of Health. 2005. Available from: http://www. clinicaltrials.gov/ct2/show/NCT 00241189term=NCT00241189&rank=1 [Updated 28 December 2005; Cited 14 October 2005]
88. Raghu G, Thickett DR. Pirfenidone for IPF. Pro/con debate; the 'con' viewpoint. Thorax 2013;68:605-8
89. Raghu G, Johnson WC, Lockhart D, et al. Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: results of a prospective, open-label phase II study. Am J Respir Crit Care Med 1999;159:1061-9 (Pubitemid 29202536)
90. Taniguchi H, Ebina M, Kondoh Y, et al. Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J 2010;35:821-9
91. Taniguchi H, Kondoh Y, Ebina M, et al. The clinical significance of 5% change in vital capacity in patients with idiopathic pulmonary fibrosis: extended analysis of the pirfenidone trial. Respir Res 2011;12:93, 9921-12-93
92. Azuma A, Taguchi Y, Ogura T, et al. Exploratory analysis of a phase III trial of pirfenidone identifies a subpopulation of patients with idiopathic pulmonary fibrosis as benefiting from treatment. Respir Res 2011;12:143, 9921-12-143
93. Tanaka K, Azuma A, Miyazaki Y, et al. Effects of lecithinized superoxide dismutase and/or pirfenidone against bleomycin-induced pulmonary fibrosis. Chest 2012;142:1011-9
94. Three-arm study of the safety and efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis. [Internet]. Washington, D.C.: National Institutes of Health. 2011. Available from: http://www.clinicaltrials.gov/ct2/ show/NCT00287716term=NCT00287716&rank=1 [Updated 12 May 2011; Cited 6 February 2006]
95. Castelino FV, Seiders J, Bain G, et al. Amelioration of dermal fibrosis by genetic deletion or pharmacologic antagonism of lysophosphatidic acid receptor 1 in a mouse model of scleroderma. Arthritis Rheum 2011; 63:1405-15
96. Yin Z, Carbone LD, Gotoh M, et al. Lysophosphatidic acid-activated clcurrent activity in human systemic sclerosis skin fibroblasts. Rheumatology (Oxford) 2010;49:2290-7
97. Yin Z, Watsky MA. Chloride channel activity in human lung fibroblasts and myofibroblasts. Am J Physiol Lung Cell Mol Physiol 2005;288:L1110-16 (Pubitemid 40695436)
98. Yin Z, Tong Y, Zhu H, et al. ClC-3 is required for LPA-activated cl-current activity and fibroblast-to-myofibroblast differentiation. Am J Physiol Cell Physiol 2008;294:C535-42 (Pubitemid 351264403)
99. Ohba T, McDonald JK, Silver RM, et al. Scleroderma bronchoalveolar lavage fluid contains thrombin, a mediator of human lung fibroblast proliferation via induction of platelet-derived growth factor alpha-receptor. Am J Respir Cell Mol Biol 1994;10:405-12
100. Proof of biological activity of SAR100842 in systemic sclerosis. [Internet]. Washington, D.C.: National Institutes of Health. 2013. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01651143 term= NCT01651143&rank=1 [Updated 8 August 2013; Cited 24 July 2012]
101. Dees C, Tomcik M, Palumbo-Zerr K, et al. JAK-2 as a novel mediator of the profibrotic effects of transforming growth factor beta in systemic sclerosis. Arthritis Rheum 2012;64:3006-15
102. Chambers RC. Procoagulant signalling mechanisms in lung inflammation and fibrosis: novel opportunities for pharmacological intervention Br J Pharmacol 2008;153(Suppl 1): S367-78 (Pubitemid 351340998)
103. Ludwicka-Bradley A, Silver RM, Bogatkevich GS. Coagulation and autoimmunity in scleroderma interstitial lung disease. Semin Arthritis Rheum 2011;41:212-22
104. Bogatkevich GS, Tourkina E, Silver RM, et al. Thrombin differentiates normal lung fibroblasts to a myofibroblast phenotype via the proteolytically activated receptor-1 and a protein kinase C-dependent pathway. J Biol Chem 2001;276:45184-92
105. Ludwicka-Bradley A, Bogatkevich G, Silver RM. Thrombin-mediated cellular events in pulmonary fibrosis associated with systemic sclerosis (scleroderma). Clin Exp Rheumatol 2004;22:S38-46 (Pubitemid 39162034)
106. Bogatkevich GS, Ludwicka-Bradley A, Silver RM. Dabigatran, a direct thrombin inhibitor, demonstrates antifibrotic effects on lung fibroblasts. Arthritis Rheum 2009;60:3455-64
107. Jungel A, Distler JH, Gay S, et al. Epigenetic modifications: novel therapeutic strategies for systemic sclerosis Expert Rev Clin Immunol 2011;7:475-80
108. Wang Y, Fan PS, Kahaleh B. Association between enhanced type I collagen expression and epigenetic repression of the FLI1 gene in scleroderma fibroblasts. Arthritis Rheum 2006;54:2271-9 (Pubitemid 44051084)
109. Zhou X, Lin W, Tan FK, et al. Decreased catalytic function with altered sumoylation of DNA topoisomerase I in the nuclei of scleroderma fibroblasts. Arthritis Res Ther 2011;13:R128
110. Khodzhigorova A, Distler A, Lang V, et al. Inhibition of sumoylation prevents experimental fibrosis. Ann Rheum Dis 2012;71:1904-8
111. Maurer B, Stanczyk J, Jungel A, et al. MicroRNA-29, a key regulator of collagen expression in systemic sclerosis. Arthritis Rheum 2010;62:1733-43
112. Zhu H, Li Y, Qu S, et al. MicroRNA expression abnormalities in limited cutaneous scleroderma and diffuse cutaneous scleroderma. J Clin Immunol 2012;32:514-22
113. Makino K, Jinnin M, Hirano A, et al. The downregulation of microRNA let-7a contributes to the excessive expression of type I collagen in systemic and localized scleroderma. J Immunol 2013; 190:3905-15
114. Beyer C, Schramm A, Akhmetshina A, et al. Beta-catenin is a central mediator of pro-fibrotic wnt signaling in systemic sclerosis. Ann Rheum Dis 2012; 71:761-7
115. Bayle J, Fitch J, Jacobsen K, et al. Increased expression of Wnt2 and SFRP4 in tsk mouse skin: role of wnt signaling in altered dermal fibrillin deposition and systemic sclerosis. J Invest Dermatol 2008;128:871-81 (Pubitemid 351374297)
116. Wei J, Fang F, Lam AP, et al. Wnt/betacatenin signaling is hyperactivated in systemic sclerosis and induces smad-dependent fibrotic responses in mesenchymal cells. Arthritis Rheum 2012;64:2734-45
117. Wu M, Schneider DJ, Mayes MD, et al. Osteopontin in systemic sclerosis and its role in dermal fibrosis. J Invest Dermatol 2012;132:1605-14
118. Barizzone N, Marchini M, Cappiello F, et al. Association of osteopontin regulatory polymorphisms with systemic sclerosis. Hum Immunol 2011;72:930-4
119. Horn A, Palumbo K, Cordazzo C, et al. Hedgehog signaling controls fibroblast activation and tissue fibrosis in systemic sclerosis. Arthritis Rheum 2012;64:2724-33
120. Horn A, Kireva T, Palumbo-Zerr K, et al. Inhibition of hedgehog signalling prevents experimental fibrosis and induces regression of established fibrosis. Ann Rheum Dis 2012;71:785-9